Role of multiparametric magnetic resonance imaging in early detection of prostate cancer

被引：39
作者：
De Visschere P.J.L. [1 ]
Briganti A. [2 ]
Fütterer J.J. [3 ]
Ghadjar P. [4 ]
Isbarn H. [5 ,6 ]
Massard C. [7 ]
Ost P. [8 ]
Sooriakumaran P. [9 ,10 ]
Surcel C.I. [11 ]
Valerio M. [12 ]
van den Bergh R.C.N. [13 ]
Ploussard G. [14 ,15 ]
Giannarini G. [16 ]
Villeirs G.M. [1 ]
机构：
[1] Department of Radiology, Ghent University Hospital, De Pintelaan 185, Ghent
[2] Department of Urology, Urological Research Institute, Vita-Salute University San Raffaele, Milan
[3] Department of Radiology and Nuclear Medicine, Radboud UMC, Nijmegen
[4] Department of Radiation Oncology, Charité Universitätsmedizin Berlin, Berlin
[5] Department of Urology, Regio Clinic Wedel, Wedel
[6] Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg
[7] Department of Oncology, Institut Gustave Roussy, University of Paris Sud, Villejuif
[8] Department of Radiation Oncology and Experimental Cancer Research, Ghent University Hospital, Ghent
[9] Surgical Intervention Trials Unit, Nuffield Department of Surgical Sciences, University of Oxford, Oxford
[10] Department of Molecular Medicine & Surgery, Karolinska Institutet, Stockholm
[11] Centre of Urological Surgery, Dialysis and Renal Transplantation, Fundeni Clinical Institute, Bucharest
[12] Department of Urology, CHUV, Lausanne
[13] Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen
[14] Urology Department, Saint Jean Languedoc Hospital, Toulouse
[15] Research Unit INSERM U955, Paris Est University, Team 7, Paris
[16] Urology Unit, Academic Medical Centre Hospital «Santa Maria della Misericordia», Udine
来源：
Insights into Imaging | 2016年 / 7卷 / 2期
关键词：
Diffusion magnetic resonance imaging; Magnetic resonance imaging; Magnetic resonance spectroscopy; Prostate; Prostatic neoplasms;
D O I：
10.1007/s13244-016-0466-9
中图分类号：
学科分类号：
摘要：
Abstract: Most prostate cancers (PC) are currently found on the basis of an elevated PSA, although this biomarker has only moderate accuracy. Histological confirmation is traditionally obtained by random transrectal ultrasound guided biopsy, but this approach may underestimate PC. It is generally accepted that a clinically significant PC requires treatment, but in case of an non-significant PC, deferment of treatment and inclusion in an active surveillance program is a valid option. The implementation of multiparametric magnetic resonance imaging (mpMRI) into a screening program may reduce the risk of overdetection of non-significant PC and improve the early detection of clinically significant PC. A mpMRI consists of T2-weighted images supplemented with diffusion-weighted imaging, dynamic contrast enhanced imaging, and/or magnetic resonance spectroscopic imaging and is preferably performed and reported according to the uniform quality standards of the Prostate Imaging Reporting and Data System (PIRADS). International guidelines currently recommend mpMRI in patients with persistently rising PSA and previous negative biopsies, but mpMRI may also be used before first biopsy to improve the biopsy yield by targeting suspicious lesions or to assist in the selection of low-risk patients in whom consideration could be given for surveillance. Teaching Points: • MpMRI may be used to detect or exclude significant prostate cancer. • MpMRI can guide targeted rebiopsy in patients with previous negative biopsies. • In patients with negative mpMRI consideration could be given for surveillance. • MpMRI may add valuable information for the optimal treatment selection. © 2016, The Author(s).
引用
收藏
页码：205 / 214
页数：9
相关论文
共 116 条
  • [1] Candefjord S., Ramser K., Lindahl O.A., Technologies for localization and diagnosis of prostate cancer, J Med Eng Technol, 33, 8, pp. 585-603, (2009)
  • [2] Schroder F.H., Roobol M.J., Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer, Curr Opin Urol, 19, 3, pp. 227-231, (2009)
  • [3] Catalona W.J., Loeb S., The PSA era is not over for prostate cancer, Eur Urol, 48, 4, pp. 541-545, (2005)
  • [4] Verbaeys C., Oosterlinck W., Prostaatspecifiek antigeen (PSA): indicatie, interpretatie en therapeutisch gevolg, Tijdschr Geneesk, 64, 12, pp. 609-613, (2008)
  • [5] Fuchsjager M., Et al., Prostate cancer imaging, Acta Radiol, 49, 1, pp. 107-120, (2008)
  • [6] Catalona W.J., Et al., Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging, Urology, 56, 2, pp. 255-260, (2000)
  • [7] De Visschere P., Et al., Clinical and imaging tools in the early diagnosis of prostate cancer, a review, JBR-BTR, 93, 2, pp. 62-70, (2010)
  • [8] Cohen M.S., Et al., Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis, Eur Urol, 54, 2, pp. 371-381, (2008)
  • [9] Djavan B., Et al., Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?, J Urol, 166, 5, pp. 1679-1683, (2001)
  • [10] Rabbani F., Et al., Incidence and clinical significance of false-negative sextant prostate biopsies, J Urol, 159, 4, pp. 1247-1250, (1998)
12345678910